Treatment with Foscarnet after Allogeneic Hematopoietic-Cell Transplant (AlloHCT) Is Associated with Long-Term Loss of Renal Function
Conclusion: Foscarnet use post AlloHCT had a profound impact on long-term renal function independent of other transplant-related factors. As declines of >30% in eGFR are strongly associated with a 10-year risk of end-stage renal disease and mortality in >60% and 50% of patients in the general population, respectively, (Coresh, et al. JAMA 2014), this information should be considered as one weighs the risks vs. benefits of treating HHV6 viremia following AlloHCT.DisclosuresHorwitz: Gamida Cell: Research Funding.
Source: Blood - Category: Hematology Authors: Foster, Y., Grant, M. J., Thomas, S. M., Cameron, B., Raiff, D., Corbet, K., Ferreri, C., Horwitz, M. E. Tags: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Poster III Source Type: research
More News: Chronic Kidney Disease | Cytomegalovirus | Grants | Herpes | Kidney Transplant | Kidney Transplantation | Study | Transplant Surgery | Transplants | Urology & Nephrology